Natixis’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $349K | Sell |
2,647
-1,257
| -32% | -$167K | ﹤0.01% | 865 |
|
|
2025
Q4 | $554K | Sell |
3,904
-1,469
| -27% | -$213K | ﹤0.01% | 820 |
|
|
2025
Q3 | $754K | Buy |
5,373
+3,091
| +135% | +$419K | ﹤0.01% | 720 |
|
|
2025
Q2 | $287K | Buy |
2,282
+1,053
| +86% | +$121K | ﹤0.01% | 763 |
|
|
2025
Q1 | $137K | Sell |
1,229
-256
| -17% | -$32.4K | ﹤0.01% | 770 |
|
|
2024
Q4 | $203K | Buy |
1,485
+918
| +162% | +$114K | ﹤0.01% | 779 |
|
|
2024
Q3 | $65.3K | Sell |
567
-572
| -50% | -$78.4K | ﹤0.01% | 771 |
|
|
2024
Q2 | $157K | Sell |
1,139
-442
| -28% | -$60.6K | ﹤0.01% | 722 |
|
|
2024
Q1 | $218K | Sell |
1,581
-323
| -17% | -$44.1K | ﹤0.01% | 705 |
|
|
2023
Q4 | $251K | Sell |
1,904
-578
| -23% | -$66.5K | ﹤0.01% | 688 |
|
|
2023
Q3 | $279K | Sell |
2,482
-19,944
| -89% | -$2.1M | ﹤0.01% | 681 |
|
|
2023
Q2 | $2.11M | Buy |
22,426
+6,001
| +37% | +$586K | 0.02% | 418 |
|
|
2023
Q1 | $1.66M | Sell |
16,425
-28,224
| -63% | -$2.94M | 0.02% | 441 |
|
|
2022
Q4 | $5.33M | Buy |
+44,649
| New | +$5.23M | 0.03% | 370 |
|
|
2022
Q3 | – | Sell |
-2,122
| Closed | -$208K | – | 1142 |
|
|
2022
Q2 | $208K | Sell |
2,122
-1,129
| -35% | -$104K | ﹤0.01% | 1031 |
|
|
2022
Q1 | $305K | Sell |
3,251
-543
| -14% | -$46K | ﹤0.01% | 1058 |
|
|
2021
Q4 | $323K | Sell |
3,794
-400
| -10% | -$36.8K | ﹤0.01% | 1121 |
|
|
2021
Q3 | $402K | Sell |
4,194
-3,230
| -44% | -$305K | ﹤0.01% | 1050 |
|
|
2021
Q2 | $723K | Buy |
+7,424
| New | +$712K | ﹤0.01% | 657 |
|
|
2021
Q1 | – | Sell |
-4,030
| Closed | -$386K | – | 1145 |
|
|
2020
Q4 | $386K | Buy |
+4,030
| New | +$389K | ﹤0.01% | 928 |
|
|
2020
Q3 | – | Sell |
-3,732
| Closed | -$455K | – | 845 |
|
|
2020
Q2 | $455K | Buy |
+3,732
| New | +$412K | ﹤0.01% | 626 |
|
|
2020
Q1 | – | Sell |
-6,121
| Closed | -$656K | – | 823 |
|
|
2019
Q4 | $656K | Buy |
+6,121
| New | +$641K | ﹤0.01% | 688 |
|
|
2019
Q2 | – | Sell |
-9,147
| Closed | -$783K | – | 850 |
|
|
2019
Q1 | $783K | Sell |
9,147
-4,101
| -31% | -$343K | ﹤0.01% | 616 |
|
|
2018
Q4 | $946K | Buy |
13,248
+1,411
| +12% | +$135K | 0.01% | 523 |
|
|
2018
Q3 | $1.46M | Buy |
+11,837
| New | +$1.34M | 0.01% | 524 |
|
|
2016
Q4 | – | Sell |
-13,424
| Closed | -$680K | – | 900 |
|
|
2016
Q3 | $680K | Buy |
13,424
+4,813
| +56% | +$240K | 0.01% | 385 |
|
|
2016
Q2 | $391K | Sell |
8,611
-280
| -3% | -$12.9K | 0.01% | 345 |
|
|
2016
Q1 | $352K | Buy |
8,891
+66
| +0.7% | +$2.62K | 0.01% | 270 |
|
|
2015
Q4 | $499K | Buy |
+8,825
| New | +$449K | 0.01% | 233 |
|
Other funds holding NBIX
VPM
VCM
Natixis's NBIX Position: Q1 2026 in Review
Natixis reduced its Neurocrine Biosciences (NBIX) stake by 32% in Q1 2026, selling an estimated $167K and leaving 2,647 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #865.
Natixis first reported a position in NBIX in Q4 2015 and has held it in 29 quarters since. The position peaked at $5.33M in Q4 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Natixis held 2,647 shares of Neurocrine Biosciences worth $349K as of Q1 2026.
- Natixis sold 1,257 Neurocrine Biosciences shares in Q1 2026, an estimated $167K.
- Neurocrine Biosciences made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #865 holding.
- Natixis first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 29 quarters since.
- Natixis's Neurocrine Biosciences position peaked at $5.33M in Q4 2022.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.